Urologix cuts jobs, loses CEO (chief executive officer), but signs deal with Boston
This article was originally published in Clinica
Executive Summary
Urologix has reduced its 130-strong workforce by 20% in an attempt to cut costs. The news comes in the wake of the company's first-quarter sales, which at $1.6 million, were below analysts' expectations. Urologix says its Targis system, which uses a proprietary microwave technology to treat benign prostatic hyperplasia, has been well accepted by academic and clinical centres, but that "the sales process in the US is complex".